论文部分内容阅读
目的观察替米沙坦联合胰激肽原酶治疗早期糖尿病肾病(DN)的疗效。方法将90例血压正常的早期糖尿病肾病患者随机分观察A组、B组及对照组。患者均在常规治疗的基础上,观察A组(替米沙坦联合胰激肽原酶)、B组(替米沙坦)及对照组各30例。12周后观察三组治疗前后患者的24 h尿微量白蛋白(Alb)、收缩压(SBP)、舒张压(DBP)、肾功能(BUN、Cr)的变化。结果观察(A、B组)24 h尿微量白蛋白较治疗前显著下降(P<0.05),与对照组比较差异有统计学意义(P<0.05),而观察A组较观察B组降低更明显,差异有统计学意义(P<0.05);其余各项指标比较差异无统计学意义。结论替米沙坦联合胰激肽原酶具有降低早期糖尿病肾病患者的24 h尿微量白蛋白的作用,并且这种作用是独立于降压之外实现的。
Objective To observe the effect of telmisartan and pancreatic kallikrein in the treatment of early diabetic nephropathy (DN). Methods Ninety patients with early normotensive diabetic nephropathy were randomly divided into group A, group B and control group. Patients on the basis of conventional treatment, observed in group A (telmisartan combined with kallikrein), group B (telmisartan) and control group of 30 cases. Twelve weeks later, 24-hour urinary albumin (Alb), SBP, DBP, BUN and Cr were observed in three groups before and after treatment. Results Compared with the control group, urine microalbumin in group A and group B decreased significantly (P <0.05), and there was significant difference compared with control group (P <0.05) Obviously, the difference was statistically significant (P <0.05); the rest of the indicators were no significant difference. Conclusion Telmisartan in combination with pancreatic kallidinogenase has the effect of reducing 24-hour urinary microalbuminuria in patients with early diabetic nephropathy, and this effect is achieved independently of antihypertensive.